PharmiWeb.com - Global Pharma News & Resources
21-Jan-2019

Pre-Close Trading Update

Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce its unaudited pre-close trading update ahead of the Group’s preliminary results for the year ended 31 December 2018.

 

Revenues on a ‘see-through’ basis* for 2018 were up 22% on the prior year (up 23% on a constant currency basis) at approximately £124.0m (2017: £101.6m, restated following the adoption of IFRS 15). Excluding acquisitions, revenues increased 4% on the prior year (4% on a constant currency basis). Underlying profit before tax is expected to be in line with expectations.

 

Our International Star brands continued to perform strongly in 2018:

  • Kelo-cote™ delivered an excellent performance, with sales increasing 68% to £22.5m (2017: £13.3m) with stronger than expected growth across the Asia Pacific region and in mainland Europe.
  • Nizoral™, the medicated anti-dandruff shampoo acquired from Johnson & Johnson (J&J) in June 2018, performed in line with expectations generating ‘see-through’ sales* of £10.9m in the second half of 2018.
  • MacuShield™ performed well with sales up 6% at £7.0m (2017: £6.6m, restated following the adoption of IFRS 15).
  • Vamousse™, acquired in December 2017, performed in line with expectations, achieving sales of £5.8m, up 16% on 2017 (under previous ownership), and up 18% on a constant currency basis.
  • Xonvea™, for the treatment of nausea and vomiting of pregnancy where conservative management has failed, was launched in October 2018 and is on track with expectations, having registered its first sales and formulary inclusions.

 

As expected, revenues from our Local brands returned a better performance in the second half of the year with sales of £40.6m (2017: £37.2m). As a result, sales of Local brands for the year were £77.8m (2017: £81.6m), down 5% on the previous year (down 5% on a constant currency basis). Going forwards, we expect sales in this portfolio to remain broadly stable and in line with the second half 2018 sales on an annualised basis.

 

Free cash flow for the year was slightly stronger than anticipated at approximately £16.1m (2017: £22.0m, restated following the adoption of IFRS 16), after allowing for costs associated with the implementation of the Falsified Medicines Directive, Brexit and launch costs relating to Xonvea. Adjusted net debt/EBITDA leverage was better than expected at approximately 2.33 times (2017: 2.46 times) and, as planned, net debt remained at similar levels to the half year-end at approximately £85.8m (30 June 2018: £86.3m). In 2019, we expect to generate strong free cash flow, which will exceed 2017 levels, and for leverage to reduce to below 2.0 times during the second half of 2019.

 

The Group expects to announce its preliminary results for the year ended 31 December 2018 on Tuesday 26 March 2019.

 

Peter Butterfield, Chief Executive Officer of Alliance Pharma, commented: “We are very pleased to report continued strong momentum in our business, with sales in 2018 up 22% compared with the previous year.  We look forward to delivering further growth in the year ahead and to employing the Group’s strong cashflow to further develop the business as the year progresses.”

 

 

* ‘See-through’ revenues include the underlying sales from Nizoral™. Under the terms of the transitional services agreement with J&J, Alliance receives the benefit of the net profit on sales of Nizoral from the date of acquisition up until the product licences in the Asia-Pacific territories transfer from J&J to Alliance, which is expected to occur during 2019 and 2020. Revenues for 2018, on a statutory-reported basis, are expected to be £118.2m, an increase of 16% on the prior year.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

 

Andrew Franklin, Chief Financial Officer

 

www.alliancepharma.co.uk

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

 

 

Numis Securities Limited

+ 44 (0)20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

 

Corporate Broking: James Black

 

 

Investec Bank plc

+ 44 (0)20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

 

Corporate Broking: Patrick Robb / Tejas Padalkar

 

Editor Details

Last Updated: 21-Jan-2019